Ketamine Maintenance Planning: Relapse, Reassessment, and Stopping Decisions

The first improvement after ketamine can raise a difficult new question: what happens next? Maintenance planning is not simply buying more sessions. It is the process of deciding whether continued treatment has a favorable balance of benefit, risk, burden, and uncertainty. A useful plan also explains what will happen if symptoms return, the treatment becomes inaccessible, or adverse effects make continuation unreasonable.

Acute benefit and maintenance are different questions

An acute trial asks whether a treatment improves symptoms over a specified short interval. A maintenance trial asks whether a strategy helps sustain an improvement or prevents relapse over a longer interval. These questions require different designs. The Murrough et al., single-infusion ketamine randomized trial, 2013 demonstrated a rapid effect after a single infusion, but its 24-hour primary outcome cannot establish the best long-term frequency, duration, or stopping procedure for repeated IV treatment.

Patients often hear that a treatment works quickly and assume it therefore works indefinitely. That conclusion does not follow. Even a genuine initial response can be followed by symptom return. Equally, a bad day does not necessarily meet a study's definition of relapse. Ask the clinician to distinguish ordinary fluctuation, partial loss of benefit, and a clinically significant depressive recurrence before using any of those terms to justify a major decision.

What the randomized withdrawal study actually tested

The Daly et al., esketamine relapse-prevention randomized trial, 2019 first treated participants with esketamine and an oral antidepressant. People who achieved stable remission or stable response could enter the randomized maintenance phase. Some continued esketamine, while others switched to placebo nasal spray; oral antidepressant treatment continued. This design directly addresses continuation among selected beneficiaries. It is more informative for that decision than a collection of testimonials, but it is not a trial of every person considering treatment.

That selection is called enrichment. It helps identify a group in whom a relapse-prevention question can be studied, while limiting how broadly the answer applies. Someone who never improved during initial treatment is not represented by the maintenance-phase success estimate in the same way. Sponsor involvement and the possibility that participants recognize treatment effects are also relevant when reviewing the report. Neither concern automatically invalidates the findings, but both belong in an honest interpretation.

Avoid transferring a schedule between products

Esketamine nasal spray and IV racemic ketamine are not interchangeable treatment programs. They differ in formulation, route, studied protocols, and regulatory framework. A maintenance schedule described in esketamine prescribing information should not be presented as a validated schedule for compounded oral ketamine or an IV infusion practice. Ask which evidence supports the exact route and regimen being proposed, rather than accepting the word ketamine as a sufficient explanation.

The Spravato prescribing information, FDA, 2025 provides a dated regulatory reference for esketamine dosing and reassessment. It should be interpreted by the prescriber alongside the person's condition and up-to-date requirements. This article is not a tapering or dose-adjustment guide. Do not skip, add, or reschedule doses independently in an attempt to reproduce a trial. When cost or transportation threatens continuity, notify the team early enough to make a safer coordinated plan.

Put the decision rules in writing

A maintenance discussion should identify the benefit being preserved. That may include a depression score, ability to manage basic activities, or return of interest in relationships. It should also define adverse effects worth reporting, review intervals, and the circumstances that would prompt reconsideration. Our treatment-record guide can help organize observations so that continuation is not based solely on how someone feels immediately after a session.

Ask how the team will distinguish a temporary setback from a need for a different strategy. Discuss other ongoing care, such as psychotherapy and management of sleep or medical illness. These are not merely background details: a maintenance plan must fit the rest of the person's life. If the only proposed response to every difficulty is another paid session, ask for a fuller explanation of alternatives and the limits of the evidence.

Prepare for interruption and deterioration

No plan should assume uninterrupted access. Ask whom to contact if an appointment is canceled, how worsening symptoms will be assessed, and which clinician remains responsible between visits. A written plan can identify support people and emergency resources without promising that ketamine prevents a crisis. The broader consultation guide explains how to evaluate care coordination before treatment begins.

If suicidal thoughts become urgent or there is an inability to stay safe, use emergency services or immediate crisis support rather than waiting for a maintenance appointment. In the United States, call or text 988; call 911 for an immediate life-threatening emergency. Maintenance research can guide a thoughtful conversation, but it cannot guarantee continued wellness or replace timely assessment when a person's condition changes substantially.

Medical disclaimer: This article provides general education, not diagnosis, individualized treatment advice, or emergency care. Evidence and regulatory statements refer to the dated sources cited, not an exhaustive verification of all changes through October 30, 2026.

Sources

1. Daly et al., esketamine relapse-prevention randomized trial, 2019
2. Murrough et al., single-infusion ketamine randomized trial, 2013
3. Spravato prescribing information, FDA, 2025